Evaluation of a trastuzumab-containing treatment regimen for patients with unresectable advanced or recurrent gastric cancer. - Wikidata - thesis-toulmin - TriplyDB

Evaluation of a trastuzumab-containing treatment regimen for patients with unresectable advanced or recurrent gastric cancer.

Evaluation of a trastuzumab-containing treatment regimen for patients with unresectable advanced or recurrent gastric cancer.

http://www.wikidata.org/entity/Q37001973

about

Poor efficacy response to trastuzumab therapy in advanced gastric cancer with homogeneous HER2 positive and non-intestinal type.Role of ARPC2 in Human Gastric Cancer.Structural basis of a novel heterodimeric Fc for bispecific antibody production.Correlation of Trastuzumab-based Treatment with Clinical Characteristics and Prognosis in HER2-Positive Gastric and gastroesophageal Junction Cancer: A retrospective single center analysis.Characterizing Metastatic HER2-Positive Gastric Cancer at the CDH1 Haplotype.Serum carbohydrate antigen 125 is a significant prognostic marker in patients with unresectable advanced or recurrent gastric cancer.Docetaxel, oxaliplatin, 5FU, and trastuzumab as first-line therapy in patients with human epidermal receptor 2-positive advanced gastric or gastroesophageal junction cancer: Preliminary results of a phase II study.

P2860

Q33779412-CAADEE97-3FE8-4298-9FB0-2098BC23E414 Q38697602-B36AC1D2-20E5-48A9-96D0-F65567EB1028 Q41612592-1FF4EEFD-9555-4BE1-8829-B0A17019B9DA Q47190729-6CA8141E-9CCB-4AD3-87E7-DE644E15F648 Q47218550-2C1B6957-27D7-4BEC-B6CB-33263225EDE1 Q47240512-EC2AAACE-599E-4BBB-B14C-E6A722BEC302 Q54109361-9B2A7BC9-699A-45B0-ABF4-ED0C531462C3

P2860

Evaluation of a trastuzumab-containing treatment regimen for patients with unresectable advanced or recurrent gastric cancer.

http://www.wikidata.org/entity/Q37001973

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 10 May 2016

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Evaluation of a trastuzumab-co ...... d or recurrent gastric cancer.

@en

Evaluation of a trastuzumab-co ...... d or recurrent gastric cancer.

@nl

type

label

Evaluation of a trastuzumab-co ...... d or recurrent gastric cancer.

@en

Evaluation of a trastuzumab-co ...... d or recurrent gastric cancer.

@nl

prefLabel

Evaluation of a trastuzumab-co ...... d or recurrent gastric cancer.

@en

Evaluation of a trastuzumab-co ...... d or recurrent gastric cancer.

@nl

P1433

Q37001973-8B810DC9-D44C-4136-8C96-3E78495D2B1A

P1476

Q37001973-EBCB3E5D-003F-4709-AC28-E7109BD8EB86

P2093

Q37001973-01E50F31-FA3D-424A-BC50-93919D7ABE67

Q37001973-375FCC0E-3A47-4B12-A0CE-3E5AB1B449B0

Q37001973-47065BC0-FA7F-438E-B1EA-559E4BFBFA59

Q37001973-8F326883-1167-4E44-BFCD-5AC61FFC7F15

Q37001973-A2CCAEFE-1801-4D92-A35B-B7C2463C3318

Q37001973-D6A11DD9-F5F2-466D-ACCB-362357137D00

Q37001973-D978C4EB-EEAE-451B-B2CE-D8D417832A95

Q37001973-E9B63958-63CF-44CD-B768-C5A99A6F89DB

Q37001973-F806AE36-91FB-47C8-9F2B-FB721222092F

P2860

Q37001973-0052962D-03AF-458C-B6E0-7519B7C9653E

Q37001973-0D76FB61-BAC1-4DA8-8DAD-596DF574E81C

Q37001973-0DB17062-7F70-4D9D-985E-D8E15E83F062

Q37001973-13DE5C8E-3E5C-4ACE-90CF-B3E95E6E9131

Q37001973-16F272D9-CAF2-47AD-A054-F0BD6B2EBF05

Q37001973-1BD69C31-5339-4DD8-9662-66BDBAB7D848

Q37001973-1EF3FE0B-D49C-4AC6-83E5-65B89B72BB02

Q37001973-23C42338-AD70-49B6-AA8E-4F2B65C48174

Q37001973-37967D79-3424-4F80-B852-0CC5C5E2AFBA

Q37001973-4AB8C9FF-FE01-4EF8-88C5-F5E150591D65

P304

Q37001973-4E0B925C-B93D-475D-B544-27F5CBFFB679

P31

Q37001973-7F7300C6-04CB-46B7-AC31-02DCC476AC32

P356

Q37001973-1E0410F5-B15A-46C9-BCD3-F8941CF644B4

P433

Q37001973-F8013DF8-46FC-4956-B3F8-6A414F90906B

P478

Q37001973-4E109957-1F42-440A-8964-52B9415B7D3C

P50

Q37001973-C5437937-D36D-4ADE-AC49-CEF3522191FF

P577

Q37001973-37ED47ED-132E-483E-B341-B85672E65841

P5875

Q37001973-45F49846-272E-45C6-9515-99929D131461

P698

Q37001973-5C0730AB-231D-41AF-9B77-28BBF2092949

P932

Q37001973-EB9E7D56-D1ED-405D-8CF7-83D24A314BDE

P356

P1433

Molecular and clinical oncology

P1476

Evaluation of a trastuzumab-co ...... ed or recurrent gastric cancer

@en

P2093

Eri Munekage

http://www.w3.org/2001/XMLSchema#string

Hiromichi Maeda

http://www.w3.org/2001/XMLSchema#string

Hiroyuki Kitagawa

http://www.w3.org/2001/XMLSchema#string

Kazuhiro Hanazaki

http://www.w3.org/2001/XMLSchema#string

Kouichi Sakamoto

http://www.w3.org/2001/XMLSchema#string

Masaya Munekage

http://www.w3.org/2001/XMLSchema#string

Masayuki Obatake

http://www.w3.org/2001/XMLSchema#string

Michiya Kobayashi

http://www.w3.org/2001/XMLSchema#string

Tsutomu Namikawa

http://www.w3.org/2001/XMLSchema#string

P2860

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.

Cancer statistics, 2015

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

THE TWO HISTOLOGICAL MAIN TYPES OF GASTRIC CARCINOMA: DIFFUSE AND SO-CALLED INTESTINAL-TYPE CARCINOMA. AN ATTEMPT AT A HISTO-CLINICAL CLASSIFICATION

Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial

Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial

HER2 screening data from ToGA: targeting HER2 in gastric and gastroesophageal junction cancer

A phase IIa dose-finding and safety study of first-line pertuzumab in combination with trastuzumab, capecitabine and cisplatin in patients with HER2-positive advanced gastric cancer

Gastric cancer treated in 2002 in Japan: 2009 annual report of the JGCA nationwide registry.

Assessment of a HER2 scoring system for gastric cancer: results from a validation study.

P304

74-78

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3892/MCO.2016.892

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

5

http://www.w3.org/2001/XMLSchema#string

P50

P577

2016-05-10T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

302916862

http://www.w3.org/2001/XMLSchema#string

P698

27330770

http://www.w3.org/2001/XMLSchema#string

P932

4907018

http://www.w3.org/2001/XMLSchema#string